Mortality and morbidity after transbronchial lung cryobiopsy

Mortality and morbidity after transbronchial lung cryobiopsy - Cryo-mortality-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026746

Enrollment

Registered

2021-09-29

Start date

2018-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DPLD = Diffuse parenchymal lung diseases

Interventions

Group 1: Patients after transbronchial lung cryobiopsy: observation of 30-day and 90-day mortality

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with radiologically proven DPLD requiring histological examination for further evaluation were chosen for inclusion in this study

Exclusion criteria

Exclusion criteria: Exclusion criteria included any possible bleeding disorders (international normalized ratio (INR) >1.3, partial thromboplastin time (PTT) above normal range, thrombocytopenia < 100.000/µl), treatment with thienopyridines, oxygen saturation below 90% after delivery of oxygen at a maximum flow rate of 2 l per minute, pre-existing severe cardiac diseases (e.g. instable angina pectoris, myocardial infarction, decompensated cardiac insufficiency) or known echocardiographically measured pulmonary hypertension with a systolic pulmonary artery pressure greater than 50 mmHg

Design outcomes

Primary

Measure	Time frame
90-day mortality	—

Secondary

Measure	Time frame
30-day mortality	—

Countries

Austria

Contacts

Public ContactKlaus Hackner

Universitätsklinikum Krems

klaus.hackner@krems.lknoe.at+43273290044368

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 13, 2026